Výsledky vyhledávání - "Douglas, Logan"

Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes

Autor: Thomas R. Alessi, Douglas Logan, Julio Rosenstock, Kenneth L. Luskey, Michelle A. Baron, Robert R. Henry

Publikováno v: Journal of Diabetes and its Complications. 28(3):393-398

Aims Evaluate the efficacy and tolerability of ITCA 650 in subjects with type 2 diabetes treated for up to 48 weeks. Methods This was a 24-week extension to a randomized, 24-week, open-label, phase 2 study in subjects with type 2 diabetes inadequatel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b34d02cc8ccd9bfc3b66565ad7aa1a9

Zobrazit plný text záznamu

The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel

Autor: Douglas Logan, Jen Fue Maa, Clement K. Ojeh, Thomas D. Nolin, Dean J. Kereiakes, Young-Hoon Jeong, Joseph A. Jakubowski, Brian A. Baker, Kevin P. Bliden, Paul A. Gurbel, Alex White, Udaya S. Tantry, Kenneth C. Lasseter, Dominick J. Angiolillo, William L. Bailey

Publikováno v: Journal of the American College of Cardiology. 62:505-512

Objectives The goal of this study was to evaluate the effect of smoking on the pharmacokinetics and pharmacodynamics (PD) of clopidogrel and prasugrel therapy. Background Major randomized trial data demonstrated that nonsmokers experience less or no

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7305a9c52afa42b7731952193824bd9
https://doi.org/10.1016/j.jacc.2013.03.037

Zobrazit plný text záznamu

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes

Autor: Douglas Logan, Julio Rosenstock, Kenneth L. Luskey, Robert R. Henry, Thomas R. Alessi, Michelle A. Baron

Publikováno v: Diabetes Care

OBJECTIVE To evaluate ITCA 650, a continuous subcutaneous miniature osmotic pump delivery system of exenatide versus twice-daily exenatide injections (Ex-BID) in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS We conducted a randomized, tw

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75dd2d4619a3f5f5d61b7f3428874223
http://europepmc.org/articles/PMC3747935

Zobrazit plný text záznamu

Recovery of Platelet Function After Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Patients With Stable Coronary Disease

Autor: James S. Walder, Douglas Logan, Matthew J. Price, Wei Li, Brian A. Baker, Dominick J. Angiolillo, Kenneth J. Winters, Darell Heiselman, Joseph A. Jakubowski

Publikováno v: Journal of the American College of Cardiology. 59(25):2338-2343

Objectives The goal of this study was to assess the offset of the antiplatelet effects of prasugrel and clopidogrel. Background Guidelines recommend discontinuing clopidogrel at least 5 days and prasugrel at least 7 days before surgery. The pharmacod

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::597de549df4e0237d5e0f6785bce2c82

Zobrazit plný text záznamu

Autor: Juan Liang, Tilo Grosser, Byron L Cryer, Jing-fei Dong, Walter Jeske, Upendra Marathi, Douglas Logan, Deepak L. Bhatt, Dominick J. Angiolillo, Andrew L. Frelinger

Publikováno v: Journal of the American College of Cardiology. 69:2879

Drs. Cerit and Duygu raise an interesting question of whether diabetic gastroparesis may play a role in apparent “aspirin resistance” in diabetic patients [(1)][1]. It is possible that in some patients, diabetic gastroparesis impairs absorption o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::722c156159d75fb46a71179374183522
https://doi.org/10.1016/j.jacc.2017.03.599

Zobrazit plný text záznamu

PHASE 1 SINGLE AND MULTIPLE ASCENDING DOSE STUDY OF CAT-2003, A NOVEL ACTIVATOR OF LIPOPROTEIN LIPASE, DEMONSTRATES REDUCTIONS IN POSTPRANDIAL TRIGLYCERIDES

Autor: Lucasz Biernat, Douglas Logan, Michael Jirousek, Maria Cecilia Mancini, Richard L. Dunbar, Michael Curtis, Joanne M. Donovan

Publikováno v: Journal of the American College of Cardiology. 63(12)

CAT-2003, an orally active small molecule, reduces fasting and postprandial triglycerides (TG) in rat models of hypertriglyceridemia (HTG) by inhibiting SREBP activation and decreasing inhibitors of lipoprotein lipase (LPL). CAT-2003, a conjugate of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6c070abf2aefb4d89816736613920b4

Zobrazit plný text záznamu

A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes

Autor: Robert R, Henry, Douglas, Logan, Thomas, Alessi, Michelle A, Baron

Publikováno v: Clinical therapeutics. 35(5)

Exenatide, a glucagon-like peptide-1 receptor agonist administered by self-injection, decreases plasma glucose, glycosylated hemoglobin (HbA1c), and weight in patients with type 2 diabetes. ITCA 650 is an investigational new drug that provides contin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b6bebccf62400eab66fb8d6c982e5090
https://pubmed.ncbi.nlm.nih.gov/23578605

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání